Biotech index gains erased, fund flows into the red

The return of drug pricing rhetoric and global stock market volatility have rocked biotech indexes over the last two weeks, wiping out most of what had been strong year-to-date gains.

Fund flows into

Read the full 330 word article

User Sign In